0000899243-22-035474.txt : 20221109 0000899243-22-035474.hdr.sgml : 20221109 20221109205108 ACCESSION NUMBER: 0000899243-22-035474 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221109 FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P. CENTRAL INDEX KEY: 0001787092 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41551 FILM NUMBER: 221374575 BUSINESS ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (617) 951-5372 MAIL ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acrivon Therapeutics, Inc. CENTRAL INDEX KEY: 0001781174 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825125532 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-207-8979 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY, SUITE 100 CITY: WATERTOWN STATE: MA ZIP: 02472 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-11-09 0 0001781174 Acrivon Therapeutics, Inc. ACRV 0001787092 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 0 0 1 0 Series B Preferred Stock Common Stock 888130 D Each share of Series B Preferred Stock is convertible into shares of Common Stock, on a 1-for-2.466 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person 2022-11-09